PRLD Stock Overview
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Prelude Therapeutics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.87 |
| 52 Week High | US$6.89 |
| 52 Week Low | US$1.66 |
| Beta | 1.5 |
| 1 Month Change | -16.05% |
| 3 Month Change | 15.87% |
| 1 Year Change | -35.71% |
| 3 Year Change | -90.20% |
| 5 Year Change | n/a |
| Change since IPO | -85.23% |
Recent News & Updates
Recent updates
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Feb 03Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Oct 18Prelude downgraded at Morgan Stanley ahead of key update
Sep 09We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
Dec 14Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Jul 05What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?
Feb 16
Prelude Therapeutics prices $150M share offering
Jan 07Prelude Therapeutics readies public offering
Jan 04Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares
Dec 25Shareholder Returns
| PRLD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.4% | -2.5% | -3.2% |
| 1Y | -35.7% | -3.7% | 19.3% |
Return vs Industry: PRLD underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: PRLD underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| PRLD volatility | |
|---|---|
| PRLD Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRLD's share price has been volatile over the past 3 months.
Volatility Over Time: PRLD's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 128 | Kris Vaddi | preludetx.com |
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company’s CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB.
Prelude Therapeutics Incorporated Fundamentals Summary
| PRLD fundamental statistics | |
|---|---|
| Market cap | US$212.44m |
| Earnings (TTM) | -US$121.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs PRLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRLD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$121.83m |
| Earnings | -US$121.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PRLD perform over the long term?
See historical performance and comparison